Journal of Movement Disorders

Original Article

Sleepiness and Depression in Parkinson’s Disease Patients Treated with Ropinirole and Levodopa: Suk Yun Kang, Ho-Sung Ryu, Mun-Kyung Sunwoo, Sang-Jin Kim, Jong-Sam Baik, Mee-Young Park, Hyung-Eun Park, Joong-Seok Kim, Kyum-Yil Kwon, Seong-Beom Koh, Young-Eun Kim, Mi-Kyong Lee, Jong-Min Kim, Sun Ju Chung, Young-Ho Sohn; J Mov Disord. 2017;10(3):123-129. Published online September 22, 2017; DOI: https://doi.org/10.14802/jmd.17048

9,719 View
195 Download
12 Web of Science
10 Crossref

Objective
We aimed to investigate the effect of ropinirole on excessive daytime sleepiness (EDS) and depression in Parkinson’s disease (PD) with a large population.
Methods
We conducted a cross-sectional observational study at nine hospitals in Korea between April 24, 2013, and April 22, 2015. We analyzed the demographic and clinical features, other medical history, history of antiparkinsonian medication within 6 months, Hoehn and Yahr stage (HY stage), Unified Parkinson’s Disease Rating Scale (UPDRS) part II and III, Epworth Sleepiness Scale (ESS), and 30-item Geriatric Depression Scale (GDS-30).
Results
Four-hundred-thirteen patients with PD (mean age: 65.2 ± 9.0 years; men: 227 patients) were analyzed. Multivariate logistic regression analysis showed that age at examination, UPDRS II, and GDS-30 were independent risk factors for EDS and that sex, UPDRS II, and ESS were independent risk factors for depression.
Conclusion
Our large group study did not find any significant associations of ropinirole with EDS and depression in Korean PD patients.

Citations

Citations to this article as recorded by

Associations between non-motor symptoms and patient characteristics in Parkinson’s disease: a multicenter cross-sectional study
Remi Morimoto, Mutsumi Iijima, Yasuyuki Okuma, Keisuke Suzuki, Fumihito Yoshii, Shigeru Nogawa, Takashi Osada, Kazuo Kitagawa
Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
Excessive Daytime Sleepiness in Parkinson’s Disease
Hanshu Liu, Jingwen Li, Xinyi Wang, Jinsha Huang, Tao Wang, Zhicheng Lin, Nian Xiong
Nature and Science of Sleep.2022; Volume 14: 1589. CrossRef
Excessive daytime sleepiness in Parkinson's disease: A systematic review and meta-analysis
Fei Feng, YingYing Cai, YanBing Hou, Ruwei Ou, Zheng Jiang, HuiFang Shang
Parkinsonism & Related Disorders.2021; 85: 133. CrossRef
Sleep Disorders and Cognitive Dysfunctions in Parkinson’s Disease: A Meta-Analytic Study
Gianpaolo Maggi, Luigi Trojano, Paolo Barone, Gabriella Santangelo
Neuropsychology Review.2021; 31(4): 643. CrossRef
Longitudinal risk factors for developing depressive symptoms in Parkinson's disease
Tarek Antar, Huw R. Morris, Faraz Faghri, Hampton L. Leonard, Mike A. Nalls, Andrew B. Singleton, Hirotaka Iwaki
Journal of the Neurological Sciences.2021; 429: 117615. CrossRef
The effect and safety of ropinirole in the treatment of Parkinson disease
Jiali Zhu, Min Chen
Medicine.2021; 100(46): e27653. CrossRef
Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson’s disease
Shi-Zhuang Wei, Xiao-Yu Yao, Chen-Tao Wang, An-Qi Dong, Dan Li, Yu-Ting Zhang, Chao Ren, Jin-Bao Zhang, Cheng-Jie Mao, Fen Wang, Chun-Feng Liu
Brain Research Bulletin.2021; 177: 363. CrossRef
A selective D2 dopamine receptor agonist alleviates depression through up-regulation of tyrosine hydroxylase and increased neurogenesis in hippocampus of the prenatally stressed rats
Mahino Fatima, Mir Hilal Ahmad, Saurabh Srivastav, Moshahid Alam Rizvi, A.C. Mondal
Neurochemistry International.2020; 136: 104730. CrossRef
‘Dopamine agonist Phobia’ in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine
Silvia Rota, Iro Boura, Lucia Batzu, Nataliya Titova, Peter Jenner, Cristian Falup-Pecurariu, K Ray Chaudhuri
Expert Review of Neurotherapeutics.2020; 20(9): 953. CrossRef
An Investigation on the Clinical Features and Neurochemical Changes in Parkinson's Disease With Depression
Teng-Hong Lian, Peng Guo, Li-Jun Zuo, Yang Hu, Shu-Yang Yu, Li Liu, Zhao Jin, Qiu-Jin Yu, Rui-Dan Wang, Li-Xia Li, Ying-Shan Piao, Wei Zhang
Frontiers in Psychiatry.2019;[Epub] CrossRef

Case Report

Treatment of Gait Ignition Failure with Ropinirole: Alexis N. Cohen-Oram, Jonathan T. Stewart, Kim Bero, Michael W. Hoffmann; J Mov Disord. 2014;7(2):95-98. Published online October 30, 2014; DOI: https://doi.org/10.14802/jmd.14014

13,298 View
39 Download
2 Web of Science
1 Crossref

Abstract PDF

Gait ignition failure (GIF) is a syndrome characterized by hesitation or inability to initiate gait from a static position. It may occur in a variety of conditions, including normal pressure hydrocephalus, subcortical vascular disease, parkinsonian syndromes and a variety of focal lesions. Previous information on the treatment of GIF has been primarily anecdotal, but there have been a few reports of response to dopamine agonists. We report a 63-year-old man with anoxic encephalopathy who developed GIF nine years after the initial anoxic insult. The patient’s GIF responded robustly, albeit transiently, to ropinirole. MRI was unrevealing, but a positron emission tomography scan showed hypometabolism in the deep frontal ACA/MCA watershed area; this may have disconnected the basal ganglia from the motor cortex and/or interrupted dopaminergic mesocortical transmission. Our understanding of the pathophysiology and the treatment of GIF remains limited, but there may be at least a limited therapeutic role for dopamine agonists.

Citations

Citations to this article as recorded by

Gait Ignition Failure in JNPL3 Human Tau-mutant Mice
HoChung Jang, Jung Hwa Ryu, Kyung Min Shin, Na-young Seo, Gyu Hyun Kim, Yang Hoon Huh, Ae Nim Pae, Kea Joo Lee
Experimental Neurobiology.2019; 28(3): 404. CrossRef

First
Prev
Page of 1
Next
Last

Search